

SPECIALTY GUIDELINE MANAGEMENT

OLUMIANT (baricitinib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Olumiant is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. For initial requests:
 - 1. Chart notes, medical record documentation, or claims history supporting previous medications tried, including response to therapy (if applicable).
 - 2. Laboratory results, chart notes, or medical record documentation of biomarker testing (i.e., rheumatoid factor [RF], anti-cyclic citrullinated peptide [anti-CCP], and C-reactive protein [CRP] and/or erythrocyte sedimentation rate [ESR]) (if applicable).
- B. For continuation requests: Chart notes or medical record documentation supporting positive clinical response.

III. CRITERIA FOR INITIAL APPROVAL

Moderately to severely active rheumatoid arthritis (RA)

- A. Authorization of 12 months may be granted for members who have previously received a biologic or targeted synthetic DMARD (e.g., Rinvoq, Xeljanz) indicated for moderately to severely active rheumatoid arthritis.
- B. Authorization of 12 months may be granted for treatment of moderately to severely active RA when all of the following criteria are met:
 - 1. Member meets either of the following criteria:
 - i. Member has been tested for either of the following biomarkers and the test was positive:
 - a. Rheumatoid factor (RF)
 - b. Anti-cyclic citrullinated peptide (anti-CCP)
 - ii. Member has been tested for ALL of the following biomarkers:
 - a. RF
 - b. Anti-CCP
 - c. C-reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)
 - 2. Member has experienced an inadequate response to at least one tumor necrosis factor (TNF) inhibitor.

Reference number
2597-A

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for an indication outlined in Section III and who achieve or maintain a positive clinical response as evidenced by disease activity improvement of at least 20% from baseline in tender joint count, swollen joint count, pain, or disability.

V. OTHER

For all indications: Member has had a documented negative TB test (which can include a tuberculosis skin test [PPD], an interferon-release assay [IGRA], or a chest x-ray)* within 6 months of initiating therapy for persons who are naïve to biologic DMARDs or targeted synthetic DMARDs associated with an increased risk of TB, and repeated yearly for members with risk factors** for TB that are continuing therapy with biologics.

* If the screening testing for TB is positive, there must be further testing to confirm there is no active disease. Do not administer the requested medication to members with active TB infection. If there is latent disease, TB treatment must be started before initiation of the requested medication.

** Risk factors for TB include: Persons with close contact to people with infectious TB disease; persons who have recently immigrated from areas of the world with high rates of TB (e.g., Africa, Asia, Eastern Europe, Latin America, Russia); children less than 5 years of age who have a positive TB test; groups with high rates of TB transmission (e.g., homeless persons, injection drug users, persons with HIV infection); persons who work or reside with people who are at an increased risk for active TB (e.g., hospitals, long-term care facilities, correctional facilities, homeless shelters).

For all indications: Member cannot use the requested medication concomitantly with any other biologic DMARD, targeted synthetic DMARD, or potent immunosuppressants such as azathioprine or cyclosporine.

VI. DOSAGE AND ADMINISTRATION

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

VII. REFERENCES

1. Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC; July 2020.
2. Tuberculosis (TB). TB risk factors. Centers for Disease Control and Prevention. Retrieved on June 3, 2021 from: <https://www.cdc.gov/tb/topic/basics/risk.htm>.
3. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis.* 2020;79:685-699.
4. Smolen JS, Aletaha D. Assessment of rheumatoid arthritis activity in clinical trials and clinical practice. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Available with subscription. URL: www.uptodate.com. Accessed March 19, 2021.
5. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthrit Care Res.* 2021;0:1-16.